secwatch.observer — SEC 8-K summary
======================================

Issuer:     Annexon, Inc. (ANNX)
CIK:        0001528115
Form:       8-K
Filed at:   2026-08-06T12:17:10+00:00
Accession:  0001193125-26-336867
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Annexon reports all 10 GBS patients in FORWARD study improved within days on tanruprubart
--------------------------------------------------------------------------------

- All 10 patients showed rapid, clinically meaningful muscle strength improvement within 4 days of single 30 mg/kg infusion.
- Four bedbound patients walked with/without assistance between day 2 and day 8; one ventilated patient off ventilator within 4 days.
- Results consistent with Phase 3 data where ~90% improved by day 8; tanruprubart generally well-tolerated.
- BLA submission targeted for Q4 2026; MAA under EMA review; GBS has ~22,000 annual U.S./Europe cases and >$20B U.S. burden.
- CEO cites decade-long commitment to C1q-targeted approach for neuroinflammatory diseases.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1528115/000119312526336867/0001193125-26-336867-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1528115/000119312526336867/d159969d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-336867

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer